Description
A glycine-conjugated form of cholic acid; has roles in the emulsification of fats; reduces expression of the gene encoding FXR and increases expression of the genes encoding the bile acid receptors TGR5 and S1PR2 in SNU-245 cells at 1.6 μmol/ml; increases the intracellular accumulation and cytotoxicity of epirubicin in Caco-2 cells at 250 μM, as well as decreases expression of the genes encoding MDR1, MRP1, and MRP2 when used alone or in combination with epirubicin; increases absorption of epirubicin into everted sacs of rat ileum and jejunum at 250 μM; bile acid composition ratio of glycocholic acid is elevated in bile of patients with cholangiocarcinoma compared with patients with pancreatic cancer or benign biliary diseases; serum levels are elevated in patients with hepatocellular carcinoma compared with healthy individuals,
Formal name: N-[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]-glycine
Synonyms: Cholylglycine|GCA
Molecular weight: 465.6
CAS: 475-31-0
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Lipids|Sterol Lipids||Research Area|Cancer|Cell Death||Research Area|Cancer|Multidrug Resistance||Research Area|Endocrinology & Metabolism|Bile Acids & Microbiome